Skip to main content

Table 2 The laboratory test results according to pulmonary CMV infection status

From: Outcomes and prognostic factors of non-HIV patients with pneumocystis jirovecii pneumonia and pulmonary CMV co-infection: A Retrospective Cohort Study

  CMV-DNA positive in BALF CMV-DNA negative in BALF p
WBC count (109/L) 7.67 ± 3.56 10.16 ± 5.51 0.08
ALT elevation, n (%) 15(39.5%) 6(18.8%) 0.06
CRP, mg/L 31.1(0.21–266) 69.1(5.18–314) 0.24
LDH, IU/L 400(151–1167) 398(181–1918) 0.79
CD4 + T lymphocyte count,/ul 223.0 ± 171.6 319.4 ± 277.9 0.13
Neutrophils in BALF, % 33(0–96) 17(3–97) 0.41
Lymphocyte in BALF,% 17(0–76) 32(0–80) 0.12
Pulmonary co-infection, n (%)
 Bacteria 18 (47.4%) 10 (31.3%) 0.17
 Fungus 12 (31.6%) 7 (21.9%) 0.36
PaO2/FiO2,n(%)
PaO2/FiO2 > 300 8(21.1%) 11 (34.4%) 0.21
200 < PaO2/FiO2 ≤ 300 10 (26.3%) 9 (28.1%) 0.86
100 < PaO2/FiO2 ≤ 200 7 (18.4%) 8 (25.0%) 0.50
PaO2/FiO2 ≤ 100 13(34.2%) 4 (12.5%) 0.04
  1. CMV cytomegalovirus, BALF bronchoalveolar lavage fluid, WBC white blood cell, ALT alanine aminotransferase, CRP C-reactive protein, LDH lactate dehydrogenase